Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGT | P01019 | 2/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991424 | 0.91 | AGT (0.58) | AGTAGTR2AGTR1 | |
| SCHEMBL809 | 0.90 | AGT (0.57) | AGTAGTR2AGTR1 | |
| SCHEMBL12991387 | 0.89 | AGT (0.56) | AGTAGTR2AGTR1 | |
| SCHEMBL9947625 | 0.89 | AGT (0.55) | AGTAGTR2AGTR1 | |
| SCHEMBL498022 | 0.89 | AGTR2 (0.63) | AGTAGTR2AGTR1 | |
| SCHEMBL12991409 | 0.88 | AGT (0.56) | AGTAGTR2AGTR1 | |
| SCHEMBL4400454 | 0.87 | AGT (0.54) | AGTAGTR2AGTR1 | |
| SCHEMBL14855371 | 0.87 | AGT (0.60) | AGTAGTR2AGTR1 | |
| SCHEMBL5036249 | 0.86 | AGT (0.53) | AGTAGTR2AGTR1 | |
| SCHEMBL14855351 | 0.86 | AGT (0.60) | AGTAGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8207208-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110065765-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | AGT 5/4885AGTR2 2/4885AGTR1 1/4885 |
| US-20110065765-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | AGT 4/4885AGTR2 2/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.